Indonesia's largest pharmaceutical company, Kalbe Farma, felt the impact of macroeconomic headwinds. The company, one of the largest public pharmaceutical companies in Southeast Asia, today announced its indicative performance (unaudited) for the year 2015. While its net sales grew 3 percent year-on-year (y/y) to IDR 17.4 trillion (approx. USD $1.3 billion), the company's net income fell 4.3 percent (y/y) to IDR 1.98 trillion (approx. USD $147 million). Kalbe Farma's performance in 2015 was plagued by weaker purchasing power in Indonesia and the depreciated rupiah exchange rate.

Lanjut baca ›

Indonesia Investments has updated the company profile of PT Kalbe Farma Tbk. Kalbe Farma is the largest listed pharmaceutical company in Indonesia and Southeast Asia (listed on the Indonesia Stock Exchange/IDX). The company’s main business focus rests on four divisions: prescription pharmaceuticals, consumer health products, nutritionals as well as distribution & logistics. Its a leading provider of “comprehensive healthcare solutions”, from pharmaceuticals, nutrition, health foods and beverages to medical devices, including primary healthcare service.

Lanjut baca ›